

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



162162

(43) International publication date

26 June 2003 (26.06.2003)

(10) International publication number

PCT

WO 03/051837 A2

(51) International patent classification⁷: C07D 209/00

(21) International application number: PCT/EP02/14344

(22) International filing date: 16 December 2002 (16.12.2002)

(25) Language of filing: German

(26) Language of publication: German

(30) Data relating to the priority:

101 64 564	14 December 2001 (14.12.2001)	DE
60/341,878	21 December 2001 (21.12.2001)	US

(71) Applicant (for all designated States except US): ZENTARIS AG [DE/DE]; Weismüllerstrasse 45, 60314 Frankfurt (DE).

(72) Inventors; and

(75) Inventors/Applicants (US only): KOPPITZ, Marcus [DE/DE]; Scharnhorstr. 28, 10115 Berlin (DE). MUHN, Hans, Peter [DE/DE]; Markgrafenstr. 61, 13465 Berlin (DE). SHAW, Ken [US/US]; 4 Buddy Lane, Brookside, NJ 07926 (US). HESS-STUMPP, Holger [DE/DE]; Wildganssteig 97, 13503 Berlin (DE). PAULINI, Klaus [DE/DE]; In der Mainau 1, 63477 Maintal (DE).

(74) Representative: DF-MP DÖRRIES FRANK-MOLNIA & POHLMAN; Triftstr. 13, 80538 Munich (DE).

(81) Designated states (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated states (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

- As to the identity of the inventor (Rule 4.17(i)) for all designations.

Published:

- Without international search report and to be republished upon receipt of that report.

For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.



G00002

As printed

(54) Title: TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR)

(54) Bezeichnung: TETRAHYDROCARBAZOLDERIVAT ALS LIGANDEN FÜR G-PROTEIN GEKOPPELTE REZEPTOREN (GPCR)

(57) Abstract: The invention relates to novel tetrahydrocarbozole derivatives acting as ligands for G-protein coupled receptors (GPCR), especially as antagonists of gonadotropin-releasing hormone (GnRH). The invention also relates to a pharmaceutical composition containing said novel tetrahydrocarbozole derivatives, and to a method for producing the same. Furthermore, the invention relates to the administration of tetrahydrocarbozole derivatives for the treatment of pathological conditions mediated by GPCR, especially for the inhibition of GnRH, to mammals, especially humans, requiring such treatment, and to the use of tetrahydrocarbozole derivatives for producing a pharmaceutical agent for treating pathological conditions mediated by GPCR, especially for the inhibition of GnRH.

(57) Zusammenfassung: Die vorliegende Erfindung stellt neue Tetrahydrocarbazol-Derivate bereit, die als Liganden für G-Protein gekoppelte Rezeptoren (GPCR), insbesondere als Antagonisten des Gonadotropin-freisetzenden Hormons (GnRH) wirken. Ferner wird eine pharmazeutische Zusammensetzung, enthaltend diese neuen Tetrahydrocarbazol-Derivate, sowie ein Verfahren zur Herstellung der neuen Tetrahydrocarbazol-Derivate bereitgestellt. Darüber hinaus betrifft die vorliegende Erfindung die Verabreichung von Tetrahydrocarbazol-Derivaten zur Behandlung von durch GPCR vermittelten Krankheitszuständen, insbesondere zur Inhibierung des GnRH, an Säugetiere, insbesondere Menschen, die eine solche Verabreichung benötigen, sowie die Verwendung von Tetrahydrocarbazol-Derivaten zur Herstellung eines pharmazeutischen Mittels zur Behandlung von durch GPCR vermittelten Krankheitszuständen, insbesondere zur Inhibierung des GnRH.

WO 03/051837 A2